Journal
MOLECULAR THERAPY
Volume 23, Issue 11, Pages 1712-1721Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/mt.2015.142
Keywords
-
Categories
Funding
- NIH [AG043540, DA028555, NS036126, NS034239, MH064570, NS043985, MH062261]
- DOD [421-20-09A]
- Carol Swarts Emerging Neuroscience Fund
- Department of Pharmacology and Experimental Neuroscience
- Shoemaker Award for Neurodegenerative Research
Ask authors/readers for more resources
Modulation of the amyloid-beta (A beta) trafficking pathway heralds a new therapeutic frontier for Alzheimer's disease (AD). As CD74 binds to the amyloid-beta precursor protein (APP) and can suppresses A beta processing, we investigated whether recombinant adeno-associated virus (AAV) delivery of CD74 could reduce A beta production and affect disease outcomes. This idea was tested in a mouse AD model. Cotransduction of AAV-tetracycline-controlled transactivator (tTA) and AAV-tet-response element -(TRE)-CD74 resulted in CD74 expression, reduced A beta production in mouse neurons containing the human APP with familial - AD-linked mutations. Stereotaxic injection of AAV-TRE-GFP or CD74 into the hippocampi of an AD mouse, defined as a TgCRND8 x calmodulin-dependent protein kinase II derived promoter-tTA doubletransgenic, reduced A beta loads and pyramidal neuronal A beta accumulation in the hippocampus. Immunofluorescent studies showed that APP colocalization with Lamp1 was increased in -CD74-expressing neurons. Moreover, Morris water maze tasks demonstrated that mice treated with AAV-TRE-CD74 showed improved learning and memory compared to AAV-TRE-GFP control animals. These results support the idea that CD74-induced alteration of A beta processing could improve AD-associated memory deficits as shown in mouse models of human disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available